Skysona and the $3 Million Toll Booth

I audit public-private invoices for a living, and Skysona arrives looking like a federal infrastructure project with a very expensive toll booth. The premise is straightforward: NIH support, academic medical centers, and basic research helped build the gene-therapy road, while bluebird bio brought a finished treatment to market with a $3 million price tag. Rare-disease therapies are complex, and private development matters. Fine. Complexity is not a magic eraser for the public role.

The money trail deserves more than an innovation ribbon-cutting. If taxpayers and public institutions carried part of the long, uncertain research burden, patients and families are entitled to ask what public return comes with the private invoice. Nobody is claiming bluebird bio did nothing; the question is who absorbed the early risk and who gets the reward when science becomes a product. Taxpayers helped pave the road. Calling the toll booth innovation does not make the receipt disappear.